In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GlaxoSmithKline plc

http://www.gsk.com

Latest From GlaxoSmithKline plc

EMA Reviews GSK/Vir’s COVID-19 Antibody To Support Early Use By Member States

After preliminary discussions with its pandemic task force, the European Medicines Agency has begun reviewing GSK/Vir Biotechnology’s promising COVID-19 treatment to help EU national competent authorities make evidence-based decisions on its possible early use.

Coronavirus COVID-19 Review Pathway

Twitchy Times At GSK As Activist Investor Takes Big Stake

GlaxoSmithKline's market value has slipped in the past three years and the number of failures in the clinic have grown. The major's leadership will be casting nervous glances towards a major shareholder that has a reputation for aggressive restructuring calls.   

Strategy Leadership

Tylenol Leads OTC Acetaminophen Sales Surge After Ibuprofen Scare During Pandemic – IRI

J&J leads sales growth in OTC pain relief and allergy categories in 2020 as its brands benefited from competing products’ problems and COVID-19’s impact of consumer habits. IRI reveals winning brands that kept a focus on maintaining health in 2020.

Market Intelligence OTC Drugs

GSK's ICOS Agonist Disappointment Another Setback For Anticancer Ambitions

GlaxoSmithKline has discontinued treatment with its ICOS agonist feladilimab in the Phase II INDUCE-3 trial upon the recommendation of the study’s data monitoring committee, another setback for the big pharma’s plans to become a major force in the cancer therapy area.

Cancer Clinical Trials
See All

Company Information

  • Industry
  • Pharmaceuticals
    • Vaccines
  • Other Names / Subsidiaries
    • ABR Development
    • Cellzome
    • Corixa Corporation
    • Fountain Acquisition Corporation
    • Genelabs Technologies, Inc.
    • GlycoVaxyn AG
    • Human Genome Sciences, Inc.
    • ID Biomedical Corporation
    • Okairos AG
    • PRAECIS Pharmaceuticals, Inc.
    • Reliant Pharmaceuticals
    • Sirtris Pharmaceuticals
    • Sitari Pharmaceuticals, Inc.
    • SmithKline Beecham
    • Stiefel Laboratories, Inc.
    • Tesaro, Inc.
    • ViiV Healthcare
UsernamePublicRestriction

Register